Drug Profile
OPB 51602
Alternative Names: OPB-51602Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Otsuka Pharmaceutical
- Class Antineoplastics
- Mechanism of Action STAT3 transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute myeloid leukaemia; Chronic myeloid leukaemia; Multiple myeloma; Nasopharyngeal cancer; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours
Most Recent Events
- 18 Jun 2015 National University Hospital in collaboration with Otsuka and Shin Nippon terminates a phase I trial in Nasopharyngeal cancer (Late-stage disease) in Singapore (NCT02058017)
- 01 Apr 2014 Otsuka Pharmaceutical completes a phase I trial in Multiple myeloma, Non-Hodgkin lymphoma, Acute myeloid leukaemia, Acute lymphoid leukaemia, Chronic myeloid leukaemia (Second-line therapy or greater) in Japan (NCT01344876)
- 17 Feb 2014 Phase 1 development is ongoing the USA, Singapore and Japan